Checkpoint blockade therapy (which targets the interaction between PD-1 and PD-L1) promotes T cell-mediated tumor immune surveillance, and has achieved remarkable clinical efficacy in various cancers, including lung cancer, melanoma, bladder cancer, renal cell cancer, and colorectal cancer (198). The gene discussed is PDCD1; the disease is neoplasm.